期刊文献+

FISH检测9号染色体GLP9 p16基因扩增在膀胱癌临床诊断中的意义 被引量:3

Clinical significance of GLP9 p16 gene amplification detected by FISH in the bladder cancer
下载PDF
导出
摘要 目的探讨GLP9 p16基因扩增在诊断膀胱癌中的临床意义。方法应用荧光标记的p16基因探针检测35例膀胱癌和10例腺性膀胱炎患者尿液脱落细胞的染色体及基因畸变情况。结果荧光显微镜下细胞核大且不规则者易观察到染色体基因异常,GLP9 p16多倍体细胞数在膀胱癌中的阳性率为85.7%(30/35),显著高于腺性膀胱炎中的阳性率10.0%(1/10)(P<0.05)。在各分期分级中GLP9 p16多倍体细胞数分别为Ta期17.3±14.9,T1期36.5±27.3,T2期61.8±21.9,T2vs.Ta(P<0.05);G1级14.5±12.0,G2级38.1±24.8,G3级73.5±12.7,随着病理分级的增高GLP9 p16多倍体细胞数显著增加(P<0.05)。结论 FISH检测GLP9 p16基因扩增对膀胱癌的临床诊断有辅助价值,同时也可以作为临床监测膀胱癌进展的一个生物学指标。 Objective To investigate the clinical significance of detecting GLP9 p16 gene amplification in the bladder cancer. Methods Fluorescence-labeled p16 gene probe was used to detect the abnormalities of chromosome 9 in the voided urine from 35 cases of bladder cancer and 10 cases of cystitis glandularis. Results Under fluorescence microscopy, large and irregular nuclei are easily observed as chromosome abnormalities. The positive rate of GLP9 p16 polyploid cells in bladder cancer was 85.7% (30/35), which was significantly higher than that of cystitis glandularis (10%, 1/10) ( P0.05). In the different stage of bladder cancer, GLP9 p16 polyploid cell number were Ta(17.3±14.9), T1(36.5±27.3), T2(61.8±21.9), respectively, and T2 vs. Ta (P0.05). Also, G1(14.5±12.0), G2(38.1±24.8), G3(73.5±12.7), respectively. Furthermore, with pathological grade up-regulated, the number of GLP9 p16 polyploid cells also increased significantly (P0.05). Conclusion GLP9 p16 gene amplification detected by FISH has important auxiliary value to diagnose bladder cancer more accurately, and can be used as a biological marker to monitor the progression of bladder cancer.
出处 《分子诊断与治疗杂志》 2012年第5期295-298,共4页 Journal of Molecular Diagnostics and Therapy
基金 国家自然科学基金(30900650H1615 81172232H1615 81172564/H1625) 广东省自然科学基金(9451008901002146) 广州市科技计划(生物医药外包服务技术平台与信息支持系统建设)
关键词 GLP9 P16基因 FISH 膀胱癌 GLP9 p16 gene FISH Bladder cancer
  • 相关文献

参考文献13

  • 1Panzeri E, Conconi D, Antolini L,et al. Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis [J]. PLoS One, 2011, 6(9): e 24237.
  • 2Fernandez M I, Parikh S, Grossman H B, et al. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer[J]. Urol Oncol, 2011. [Epub ahead of print].
  • 3Lindemann-Docter K, Gaisa N T, Smeets D, et al. Urine markers with special regard to fluorescent in situ hybridization (FISH) [J]. Urologe A, 2011, 50(3): 297-302.
  • 4Kamat A M, Karam J A, Grossman H B, et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity[J]. BJU Int, 2011, 108(7): 1119-1123.
  • 5Ding T, Wang Y K, Cao Y H, et al. Clinical utility of fluorescence in situ hybridization for prediction of residual tumor after transurethral resection of bladder urothelial carcinoma[J]. Urology, 2011, 77(4): 855-859.
  • 6Mian C, Mazzoleni G, Vikoler S, et al. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours[J]. Eur Urol, 2010, 58(2): 288-292.
  • 7Vit V, Pacik D, Cermik A, et al.Our experience in using fluorescence in situ hybridization FISH-Uro Vysion in diagnostics of urothelial carcinoma[J]. Cesk Patol, 2009, 45(2): 46-49.
  • 8Altieri V M, Castellucci R, Palumbo P, et al. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables[J]. Urol Int, 2012, 89(1): 61-66.
  • 9Ploeg M, Aben K K, Kiemeney L A. The present and future burden of urinary bladder cancer in the world[J]. World J Urol, 2009, 27(3): 289-293.
  • 10Sylvester R J. How well can you actually predict which non- muscle-invasive bladder cancer patients will progress? [J]. Eur Urol, 2011, 60(3): 431-433.

同被引文献25

  • 1易翔,黄茜,郑晓婉,张志栋.应用Methylight法检测胃癌病人p16基因的甲基化状态[J].临床检验杂志(电子版),2012,1(2):125-126. 被引量:1
  • 2韩志敏.人毛乳头细胞中P16基因的检测及意义[J].河北医科大学,2012,21(6):106-107.
  • 3张继华,李晓,张毅,等.P16基因甲基化检测在肺癌早期诊断中的应用研究[J].中外健康文摘,2013,11(46):102-103.
  • 4Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion Assay) [J]. Adv Anat Pathol, 2008,15 (5) :279- 286.
  • 5Xu CL, Zeng QS, Hou JG, et al. Utility of a modality combining fish and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients [ J ]. Urology, 2011,77 (3) : 636-641.
  • 6Petrov SV, Malkhasyan KA, Ulyanin MY, et al. The value of the preopera tive FISH test in unscreened bladder cancer patients with TUR indications [J]. Pathol Oncol Res, 2012,18 (4) : 1059-1066.
  • 7Sevankaev A, Lushnikov E, Karyakin O, et al. Clinical use of the FISH method in early detection of superficial bladder cancer [J]. Oneourology, 2008, 4 : 61-65.
  • 8Riesz P, Lotz G, Paska C, et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique [J]. Pathol Oncol Res, 2007,13(3) : 187-194.
  • 9Jones JS. DNA-based molecular cytology for bladder cancer surveillance [ J ]. Urology, 2006,67 ( 3 ) : 35.
  • 10Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium [J]. Urol Oncol, 2010,28 (4) : 409 -428.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部